June 17, 2025
3 min watch
CHICAGO — On this video, Susana M. Campos, MD, MPH, discusses outcomes from a part 3 medical trial of dostarlimab and niraparib in superior ovarian most cancers, introduced at ASCO Annual Assembly.
The FIRST/ENGOT-OV44 trial evaluated including dostarlimab (Jemperli, GSK) to platinum-based chemotherapy and niraparib (Zejula, GSK) upkeep, with or with out bevacizumab (Avastin, Genentech), in sufferers with stage III-IV ovarian most cancers.
“There was a constructive progression-free survival profit with the arm that utilized the immunotherapy,” Campos, medical director of the division of gynecologic oncology at Dana-Farber Most cancers Institute and assistant professor of medication at Harvard Medical Faculty, mentioned. “Nonetheless, the important thing ingredient was that this was a really clinically modest enchancment, actually taking a look at a distinction between the 2 arms of about 1.4 months. Moreover, there was no statistically vital profit by way of general survival.”
Reference:
Hardy-Bessard AC, et al. Summary LBA5506. Introduced at: ASCO Annual Assembly; Could 30-June 3, 2025; Chicago.
